The need for cost-effective choices to treat patients with bipolar 1 disorders including asenapine

Research output: Contribution to journalEditorial

Abstract

Bipolar 1 disorders (BPD) are a chronic disorder with prevalence rates up to 2.6% of the adult population or higher and appreciable direct and indirect costs. As a result, a concern to health authorities especially given the low age of onset. Consequently, a need to treat BPD patients well and improve their quality of life. Pharmacotherapy includes mood stabilisers and atypical antipsychotics (AAPs). AAPs have different mechanisms of action and side-effects so treatment needs to be tailored. Asenapine in clinical trials is as effective as olanzapine with less metabolic side-effects. Chitnis and colleagues have shown in routine care that asenapine also reduces hospital and emergency room admissions making it cost neutral in BPD, which is of interest to health authorities and clinicians.
LanguageEnglish
Pages871-873
Number of pages3
JournalJournal of Medical Economics
Volume18
Issue number11
Early online date26 Aug 2015
DOIs
Publication statusPublished - 2 Nov 2015

Fingerprint

Bipolar Disorder
olanzapine
Costs and Cost Analysis
Antipsychotic Agents
Health
Age of Onset
Hospital Emergency Service
Quality of Life
Clinical Trials
Drug Therapy
Population
Asenapine
Therapeutics

Keywords

  • bipolar 1 disorders
  • pharmacotherapy
  • asenapine

Cite this

@article{d0a62ade02f24bcd9cee3767daf86aff,
title = "The need for cost-effective choices to treat patients with bipolar 1 disorders including asenapine",
abstract = "Bipolar 1 disorders (BPD) are a chronic disorder with prevalence rates up to 2.6{\%} of the adult population or higher and appreciable direct and indirect costs. As a result, a concern to health authorities especially given the low age of onset. Consequently, a need to treat BPD patients well and improve their quality of life. Pharmacotherapy includes mood stabilisers and atypical antipsychotics (AAPs). AAPs have different mechanisms of action and side-effects so treatment needs to be tailored. Asenapine in clinical trials is as effective as olanzapine with less metabolic side-effects. Chitnis and colleagues have shown in routine care that asenapine also reduces hospital and emergency room admissions making it cost neutral in BPD, which is of interest to health authorities and clinicians.",
keywords = "bipolar 1 disorders, pharmacotherapy, asenapine",
author = "Brian Godman",
note = "This is an Accepted Manuscript of an article published by Taylor & Francis in Journal of Medical Economics on 26 August 2015, available online: http://wwww.tandfonline.com/10.3111/13696998.2015.1073736.",
year = "2015",
month = "11",
day = "2",
doi = "10.3111/13696998.2015.1073736",
language = "English",
volume = "18",
pages = "871--873",
journal = "Journal of Medical Economics",
issn = "1369-6998",
number = "11",

}

The need for cost-effective choices to treat patients with bipolar 1 disorders including asenapine. / Godman, Brian.

In: Journal of Medical Economics, Vol. 18, No. 11, 02.11.2015, p. 871-873.

Research output: Contribution to journalEditorial

TY - JOUR

T1 - The need for cost-effective choices to treat patients with bipolar 1 disorders including asenapine

AU - Godman, Brian

N1 - This is an Accepted Manuscript of an article published by Taylor & Francis in Journal of Medical Economics on 26 August 2015, available online: http://wwww.tandfonline.com/10.3111/13696998.2015.1073736.

PY - 2015/11/2

Y1 - 2015/11/2

N2 - Bipolar 1 disorders (BPD) are a chronic disorder with prevalence rates up to 2.6% of the adult population or higher and appreciable direct and indirect costs. As a result, a concern to health authorities especially given the low age of onset. Consequently, a need to treat BPD patients well and improve their quality of life. Pharmacotherapy includes mood stabilisers and atypical antipsychotics (AAPs). AAPs have different mechanisms of action and side-effects so treatment needs to be tailored. Asenapine in clinical trials is as effective as olanzapine with less metabolic side-effects. Chitnis and colleagues have shown in routine care that asenapine also reduces hospital and emergency room admissions making it cost neutral in BPD, which is of interest to health authorities and clinicians.

AB - Bipolar 1 disorders (BPD) are a chronic disorder with prevalence rates up to 2.6% of the adult population or higher and appreciable direct and indirect costs. As a result, a concern to health authorities especially given the low age of onset. Consequently, a need to treat BPD patients well and improve their quality of life. Pharmacotherapy includes mood stabilisers and atypical antipsychotics (AAPs). AAPs have different mechanisms of action and side-effects so treatment needs to be tailored. Asenapine in clinical trials is as effective as olanzapine with less metabolic side-effects. Chitnis and colleagues have shown in routine care that asenapine also reduces hospital and emergency room admissions making it cost neutral in BPD, which is of interest to health authorities and clinicians.

KW - bipolar 1 disorders

KW - pharmacotherapy

KW - asenapine

UR - http://www.tandfonline.com/doi/full/10.3111/13696998.2015.1073736

U2 - 10.3111/13696998.2015.1073736

DO - 10.3111/13696998.2015.1073736

M3 - Editorial

VL - 18

SP - 871

EP - 873

JO - Journal of Medical Economics

T2 - Journal of Medical Economics

JF - Journal of Medical Economics

SN - 1369-6998

IS - 11

ER -